Astellas Pharma Inc announced dosing of the first patient in the SKYLIGHT 1 phase 3 pivotal trial for fezolinetant, an investigational oral, non─hormonal compound being studied for the treatment of moderate─to─severe vasomotor symptoms
Ook interessant voor je
Pharmazz begins patient dosing in phase 3 study of sovateltide to treat acute cerebral ischemic stroke
Sovateltide Pharmazz, Inc, a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients in critical care, announced the initiation of dosing in its pivotal, phase...
1 x gelezen
Europe approves Keytruda for first-line head and neck squamous cell carcinoma, as a monotherapy or combo
MSD’s top-selling immunotherapy Keytruda (pembrolizumab) has secured another approval from the European Commission, this time in the first-line treatment of metastatic or unresectable recurrent head and neck squamous...
12 x gelezen
Bristol-Myers misses main goal of late-stage skin cancer trial
late-stage skin cancer trial Bristol-Myers Squibb Co said on Wednesday its late-stage trial testing a combination of its cancer drugs missed a main goal of preventing skin cancer from recurring in a certain group of...
1 x gelezen